Qualitative Differential Screening
First Claim
1. A device for identifying at least one differentially spliced gene product, wherein said device comprisesa solid support material and single-stranded oligonucleotides of between 5 and 100 nucleotides in length attached to said support material,wherein said oligonucleotides comprise at least a first and a second oligonucleotide molecule arranged serially on the support material,wherein said first oligonucleotide molecule comprises a first sequence that is complementary to and specific for a first exon or exon-exon or exon-intron junction region of a first gene or RNA, and wherein said first sequence corresponds to a region of variability in at least one product of said first gene due to differential splicing, andwherein said second oligonucleotide molecule comprises a second sequence that is complementary to and specific for a second exon or exon-exon or exon-intron junction region of said first gene or RNA, and wherein said second sequence corresponds to a region of variability in at least one product of said first gene due to differential splicing,said device allowing, when contacted with a diverse population of nucleic acid molecules prepared from a biological sample under conditions allowing hybridisation to occur, the determination of the presence or absence of said differentially spliced gene product.
2 Assignments
0 Petitions
Accused Products
Abstract
The invention concerns a method for identifying and/or cloning nucleic acid regions representing qualitative differences associated with alternative splicing events and/or with insertions, deletions located in RNA transcribed genome regions, between two physiological situations, comprising either hybridization of RNA derived from the test situation with cDNA'"'"'s derived from the reference situation and/or reciprocally, or double-strand hybridization of cDNA derived from the test situation with cDNA'"'"'s derived from the reference situation; and identifying and/or cloning nucleic acids representing qualitative differences. The invention also concerns compositions or banks of nucleic acids representing qualitative differences between two physiological situations, obtainable by the above method, and their use as probe, for identifying genes or molecules of interest, or still for example in methods of pharmacogenomics, and profiling of molecules relative to their therapeutic and/or toxic effects. The invention further concerns the use of dysregulation of splicing RNA as markers for predicting molecule toxicity and/or efficacy, and as markers in pharmacogenomics.
-
Citations
32 Claims
-
1. A device for identifying at least one differentially spliced gene product, wherein said device comprises
a solid support material and single-stranded oligonucleotides of between 5 and 100 nucleotides in length attached to said support material, wherein said oligonucleotides comprise at least a first and a second oligonucleotide molecule arranged serially on the support material, wherein said first oligonucleotide molecule comprises a first sequence that is complementary to and specific for a first exon or exon-exon or exon-intron junction region of a first gene or RNA, and wherein said first sequence corresponds to a region of variability in at least one product of said first gene due to differential splicing, and wherein said second oligonucleotide molecule comprises a second sequence that is complementary to and specific for a second exon or exon-exon or exon-intron junction region of said first gene or RNA, and wherein said second sequence corresponds to a region of variability in at least one product of said first gene due to differential splicing, said device allowing, when contacted with a diverse population of nucleic acid molecules prepared from a biological sample under conditions allowing hybridisation to occur, the determination of the presence or absence of said differentially spliced gene product.
-
14-22. -22. (canceled)
Specification